Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Image_5_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

“…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”

Effect of selected feed additives to improve growth and health of dairy calves by Luisa F. L. Salazar (6664121)

“…The treatments were: control (CON), monensin (MON; 30 mg/kg of starter), probiotic <i>E</i>. <i>faecium</i> (PROB; 70 mg/kg of starter), essential oils (EO; 300 mg/kg of starter), or PROB + EO (EOPROB). …”

Fig 2 - by Nida Mansoora (11648641)

Subjects:

Fig 3 - by Nida Mansoora (11648641)

Subjects:

Fig 4 - by Nida Mansoora (11648641)

Subjects:

Fig 1 - by Nida Mansoora (11648641)

Subjects:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... by Nida Mansoora (11648641)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…<p>(<b>A–B</b>) Bath perfusion of DHPG for 3 min reduced GlyR-IPSCs (<b>A</b>; 70.2 ± 4.2% of baseline at 15–20 min post-DHPG, <i>t</i>[16] = 6.707, <i>p</i> < 0.001, paired Student <i>t</i> test), but not GABA_A-receptor–mediated IPSCs (<b>B</b>; 102.9 ± 3.3% of baseline at 15–20 min post-DHPG, <i>t</i>[5] = 0.347, <i>p</i> = 0.743) in spinal slices of mice. …”

Decreased expression of V-ATPase upon the siRNA transfection. by Manisha Naskar (2613763)

Decreased expression of ATG5 upon the siRNA transfection. by Manisha Naskar (2613763)